Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 1/20 | 0.58 |
| ▸ | CNR2 | P34972 | 11/20 | 0.58 |
| ▸ | FLT3 | P36888 | 4/20 | 0.54 |
| ▸ | CNR1 | P21554 | 7/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | CASP3 | P42574 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.51 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5453563 | 0.85 | CFTR (0.52) | CFTRCNR2CNR1NPC1RAB9A | |
| SCHEMBL5467114 | 0.83 | CFTR (0.64) | CFTRCNR2FLT3NPC1RAB9A | |
| SCHEMBL5450945 | 0.80 | CFTR (0.54) | CFTRCNR2CNR1NPC1RAB9A | |
| SCHEMBL17988129 | 0.79 | KMT2A (0.58) | FLT3NPC1RAB9AMEN1CASP3 | |
| SCHEMBL5447523 | 0.79 | CFTR (0.56) | CFTRCNR2CNR1NPC1RAB9A | |
| SCHEMBL5459988 | 0.78 | ANO1 (0.53) | CFTRCNR2CNR1MEN1KMT2A | |
| SCHEMBL5457748 | 0.78 | FLT3 (0.71) | CFTRCNR2FLT3NPC1RAB9A | |
| SCHEMBL4139722 | 0.78 | ANO1 (0.71) | CNR2CNR1 | |
| SCHEMBL19475104 | 0.78 | CFTR (0.65) | CFTRCNR2CNR1NPC1RAB9A | |
| SCHEMBL17988122 | 0.77 | KMT2A (0.59) | FLT3MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070275962-A1 | Heterobicyclic Compounds as Pharmaceutically Active Agents | GPC BIOTECH AG (DE) | 2007-11-29 | — | — | US | claimed |
| US-20070275962-A1 | Heterobicyclic Compounds as Pharmaceutically Active Agents | GPC BIOTECH AG (DE) | 2007-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275962-A1 | Heterobicyclic Compounds as Pharmaceutically Active Agents | TBCA, PARK7, NFATC1 | CFTR 2030/4885CNR2 2272/4885FLT3 3509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.